TY - JOUR AU - Dickhoff, Chris AU - Senan, Suresh AU - Schneiders, Famke L. AU - Veltman, Joris AU - Hashemi, Sayed AU - Daniels, Johannes M. A. AU - Fransen, Marieke AU - Heineman, David J. AU - Radonic, Teodora AU - van de Ven, Peter M. AU - Bartelink, Imke H. AU - Meijboom, Lilian J. AU - Garcia-Vallejo, Juan J. AU - Oprea-Lager, Daniela E. AU - de Gruijl, Tanja D. AU - Bahce, Idris PY - 2020 DA - 2020/08/14 TI - Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0–1 non-small cell lung cancer: the INCREASE trial JO - BMC Cancer SP - 764 VL - 20 IS - 1 AB - The likelihood of a tumor recurrence in patients with T3-4N0–1 non-small cell lung cancer following multimodality treatment remains substantial, mainly due distant metastases. As pathological complete responses (pCR) in resected specimens are seen in only a minority (28–38%) of patients following chemoradiotherapy, we designed the INCREASE trial (EudraCT-Number: 2019–003454-83; Netherlands Trial Register number: NL8435) to assess if pCR rates could be further improved by adding short course immunotherapy to induction chemoradiotherapy. Translational studies will correlate changes in loco-regional and systemic immune status with patterns of recurrence. SN - 1471-2407 UR - https://doi.org/10.1186/s12885-020-07263-9 DO - 10.1186/s12885-020-07263-9 ID - Dickhoff2020 ER -